Combination therapy after surgery for mixed liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, cadonilimab and capecitabine, given after surgery to remove a rare type of liver cancer that has both hepatocellular and cholangiocarcinoma features. The goal is to see if this treatment helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had surgery to completely remove your liver cancer, and the cancer is a mix of two types (hepatocellular and intrahepatic cholangiocarcinoma).
- Your cancer has not spread outside the liver.
- Your liver function is good (Child-Pugh class A) and you are otherwise in good health (ECOG score 0 or 1).
- If you have hepatitis B or C, it must be well controlled with antiviral medication.
- You have not had any other cancer recently, and you do not have active autoimmune diseases or serious heart, lung, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with a rare and advanced liver cancer called combined hepatocellular cholangiocarcinoma (CHC). Doctors will use information from your tumor and health history to find the best treatment approach for your specific cancer type.
This trial tests two drugs (THIO and cadonilimab) given before surgery to see if they help shrink liver cancer that can be removed. It is for people with early-stage liver cancer who are candidates for surgery.
This trial tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) with standard chemotherapy (gemcitabine and cisplatin) for a rare type of liver cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a combination of liver-directed chemotherapy (given through a small tube into the liver artery), targeted therapy, and an immunotherapy drug (a PD-1 inhibitor) to help prevent liver cancer from coming back after surgery. It is for people whose tumor showed microvascular invasion, which raises the risk of recurrence.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This study tests a combination of three treatments (HAIC, lenvatinib, and cadonilimab) as a way to shrink liver tumors that cannot be removed with surgery. The goal is to make the tumors smaller so they might be removed later, and to see how safe and effective this combination is.
Hear when a new Combined Hepatocellular-cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.